These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 1428461

  • 21. Skin penetration behaviour of liposomes as a function of their composition.
    Gillet A, Lecomte F, Hubert P, Ducat E, Evrard B, Piel G.
    Eur J Pharm Biopharm; 2011 Sep; 79(1):43-53. PubMed ID: 21272638
    [Abstract] [Full Text] [Related]

  • 22. The evaluation of a novel corticosteroid formulation, fluocinonide in "FAPG" base, in the blanching test.
    Coldman MF, Lockerbie L, Laws EA.
    Br J Dermatol; 1971 Dec; 85(6):573-6. PubMed ID: 4947552
    [No Abstract] [Full Text] [Related]

  • 23. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay.
    Cornell RC.
    Int J Dermatol; 1992 Oct; 31 Suppl 1():38-40. PubMed ID: 1428467
    [Abstract] [Full Text] [Related]

  • 24. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E, Smith EW, Haigh JM, Kanfer I.
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [Abstract] [Full Text] [Related]

  • 25. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling.
    Singh GJ, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, Pershing LK.
    Clin Pharmacol Ther; 1999 Oct; 66(4):346-57. PubMed ID: 10546918
    [Abstract] [Full Text] [Related]

  • 26. [Skin vasoconstriction assay in the evaluation of topical corticosteroids in man. General problems and results obtained in a series of tests (author's transl)].
    Weirich EG, Lutz U.
    Dermatologica; 1973 Oct; 147(6):353-75. PubMed ID: 4788215
    [No Abstract] [Full Text] [Related]

  • 27. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis.
    Sonawane R, Harde H, Katariya M, Agrawal S, Jain S.
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1833-47. PubMed ID: 25078031
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.
    Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML.
    Clin Pharmacokinet; 2015 Nov; 54(11):1095-106. PubMed ID: 26063051
    [Abstract] [Full Text] [Related]

  • 29. Effect of topical vasoconstrictor exposure upon tumoricidal radiotherapy.
    Fahl WE.
    Int J Cancer; 2014 Aug 15; 135(4):981-8. PubMed ID: 24470435
    [Abstract] [Full Text] [Related]

  • 30. Bioequivalence (bioavailability) of generic topical corticosteroids.
    Jackson DB, Thompson C, McCormack JR, Guin JD.
    J Am Acad Dermatol; 1989 May 15; 20(5 Pt 1):791-6. PubMed ID: 2715430
    [Abstract] [Full Text] [Related]

  • 31. Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome.
    Gillet A, Grammenos A, Compère P, Evrard B, Piel G.
    Int J Pharm; 2009 Oct 01; 380(1-2):174-80. PubMed ID: 19576972
    [Abstract] [Full Text] [Related]

  • 32. Vehicle design for a new topical steroid, fluocinonide.
    Ostrenga J, Haleblian J, Poulsen B, Ferrell B, Mueller N, Shastri S.
    J Invest Dermatol; 1971 May 01; 56(5):392-9. PubMed ID: 5556528
    [No Abstract] [Full Text] [Related]

  • 33. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids.
    Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH.
    Eur J Dermatol; 2011 May 01; 21(5):710-6. PubMed ID: 21708519
    [Abstract] [Full Text] [Related]

  • 34. Quantification of corticosteroid-induced skin vasoconstriction: visual ranking, chromameter measurement or digital imaging analysis.
    Smith EW, Haigh JM, Surber C.
    Dermatology; 2002 May 01; 205(1):3-10. PubMed ID: 12145427
    [Abstract] [Full Text] [Related]

  • 35. Bioequivalence of topical corticosteroids: a regulatory perspective.
    Williams RL.
    Int J Dermatol; 1992 Oct 01; 31 Suppl 1():2-5. PubMed ID: 1428462
    [Abstract] [Full Text] [Related]

  • 36. The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol 17-propionate in vivo.
    Watson WS, Finlay AY.
    Br J Dermatol; 1988 Apr 01; 118(4):523-30. PubMed ID: 3377973
    [Abstract] [Full Text] [Related]

  • 37. Bioavailability of betamethasone dipropionate when combined with calcipotriol.
    Traulsen J.
    Int J Dermatol; 2004 Aug 01; 43(8):611-7. PubMed ID: 15304191
    [Abstract] [Full Text] [Related]

  • 38. Progress in methodologies for evaluating bioequivalence of topical formulations.
    Shah VP.
    Am J Clin Dermatol; 2001 Aug 01; 2(5):275-80. PubMed ID: 11721645
    [Abstract] [Full Text] [Related]

  • 39. Effects of topical corticosteroid and tacrolimus on ceramides and irritancy to sodium lauryl sulphate in healthy skin.
    Jungersted JM, Høgh JK, Hellegren LI, Jemec GB, Agner T.
    Acta Derm Venereol; 2011 May 01; 91(3):290-4. PubMed ID: 21365172
    [Abstract] [Full Text] [Related]

  • 40. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations.
    Borsadia S, Ghanem AH, Seta Y, Higuchi WI, Flynn GL, Behl CR, Shah VP.
    Skin Pharmacol; 1992 May 01; 5(3):129-45. PubMed ID: 1445703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.